Companion Animal Pharmaceuticals Market Forecast Showing $29.1 Billion by 2030 at 10.3% CAGR

April 8, 2026April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Alzheimer’s Disease Treatment Market During 2026–2030?

The companion animal pharmaceuticals market has seen rapid growth in recent years. It is anticipated to increase from $17.85 billion in 2025 to $19.65 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.1%. The expansion observed historically can be attributed to the rising incidence of infectious diseases in dogs and cats, an increase in veterinary clinics and hospitals, heightened awareness regarding companion animal health, the introduction of vaccines and antiparasitic drugs, and the early adoption of anti-inflammatory therapies.

The companion animal pharmaceuticals market size is projected to experience swift expansion in the coming years, with expectations to reach $29.14 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth throughout the forecast period is propelled by advancements in precision medicine for companion animals, the increasing adoption of digital prescription management, a surge in preventive healthcare and vaccination programs, the escalating demand for specialized behavioral and orthopedic therapeutics, and the broader expansion of veterinary retail pharmacy networks. Prominent trends foreseen during this forecast period involve a heightened demand for companion animal vaccines, the rising adoption of anti-inflammatory and pain management drugs, a growth in behavioral and dermatologic therapeutics, the expansion of veterinary retail pharmacies and clinics, and the customization of drug formulations to suit specific companion animals.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7983&type=smp

Which Major Factors Are Driving The Expansion Of The Alzheimer’s Disease Treatment Market?

The increasing occurrence of zoonotic illnesses is anticipated to drive the expansion of the companion animal pharmaceuticals market in the future. A zoonotic ailment is defined as a condition that can naturally spread between vertebrate animals and humans. The rise in human-animal contact leads to a surge in zoonotic diseases, facilitating greater chances for pathogens to transfer from animals to people, thereby quickening the dissemination of infections. Companion Animal Pharmaceuticals assist in managing zoonotic conditions by providing drugs and preventative therapies that decrease pet infections, consequently reducing the likelihood of human transmission. For example, data from February 2023, published by the Council on Foreign Relations (CFR)—a US-based independent, nonpartisan member organization, think tank, and publisher—indicates that as much as 75% of newly identified or emerging infectious diseases (EIDs) and 60% of established infectious diseases originate from zoonoses. Globally, zoonoses are responsible for 2.7 million human deaths and 2.5 billion disease incidents among people annually. Consequently, the expanding occurrence of zoonotic diseases is propelling the growth of the companion animal pharmaceuticals market.

How Are The Various Segments Of The Alzheimer’s Disease Treatment Market Categorized?

The companion animal pharmaceuticals market covered in this report is segmented –

1) By Product Type: Therapeutic Drugs, Vaccines, Other Product Types

2) By Animal Type: Dogs, Cats, Equines, Other Animal Types

3) By Route Of Administration: Oral, Injectable, Topical, Inhalation, Other Route Of Administrations

4) By Distribution Channel: Veterinary Hospitals And Clinics, Retail Pharmacies, Online Pharmacies Or E Commerce, Veterinary Distributors, Direct Sales

5) By End User: Veterinarians, Pet Owners, Animal Care Centers, Pet Specialty Stores

Subsegments:

1) By Therapeutic Drugs: Anti infectives, Cardiovascular Drugs, Hormonal And Metabolic Drugs, Dermatological Drugs, Pain Relief And Anti Inflammatory Drugs, Gastrointestinal Drugs, Respiratory Drugs, Central Nervous System (CNS) Drugs

2) By Vaccines: Bacterial Vaccines, Viral Vaccines, Combination Vaccines

3) By Other Product Types: Nutraceuticals And Supplements, Specialty Pharmaceuticals

What Trends Are Affecting The Expansion Of The Companion Animal Pharmaceuticals Market?

Leading companies within the companion animal pharmaceutical market are introducing innovative products, such as oral flea and tick products, to attract larger customer bases, boost sales, and increase revenue. Oral flea and tick products are medications administered orally to pets for the prevention or treatment of flea and tick infestations. For instance, in October 2024, Elanco Animal Health Incorporated, a US-based pharmaceutical company, announced FDA approval for Credelio Quattro, a new chewable parasiticide formulated for dogs. This product offers monthly protection against six types of parasites, including fleas, ticks, and several internal worms. With Credelio Quattro, Elanco aims to deliver a convenient, comprehensive solution for pet owners seeking broad-spectrum parasite control. This launch demonstrates Elanco’s commitment to satisfying the growing demand for inventive and effective pet health solutions.

Which Major Firms Influence Developments In The Alzheimer’s Disease Treatment Market?

Major companies operating in the companion animal pharmaceuticals market are Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Inovet Group, Merck & Co. Inc., Norbrook Laboratories Ltd., Vetoquinol S.A., Virbac S.A., Zoetis Inc., Eli Lilly and Company, IDEXX Laboratories Inc., Merial Limited, Dechra Pharmaceuticals PLC, Aratana Therapeutics Inc., Kindred Biosciences Inc., Jaguar Health Inc., Nexvet Biopharma PLC, PetMed Express Inc., Heska Corporation, Synbiotics Corporation, Eurovet Animal Health B.V., Abaxis Inc., Putney Inc.

Read the full companion animal pharmaceuticals market report here:

https://www.thebusinessresearchcompany.com/report/companion-animal-pharmaceuticals-global-market-report

Which Region Currently Holds The Largest Share Of The Alzheimer’s Disease Treatment Market?

North America was the largest region in the companion animal pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the companion animal pharmaceuticals market report during the forecast period. The regions covered in the companion animal pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Alzheimer’s Disease Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7983&type=smp

Browse Through More Reports Similar to the Global Companion Animal Pharmaceuticals Market 2026, By The Business Research Company

Veterinary Pharmaceuticals Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

Veterinary Pharmaceuticals Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

Animal Medicine Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/animal-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795